Related Experiment Video
Updated: Dec 25, 2025
Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
Published on: July 6, 2022
Reactivation of FMR1 gene expression is a promising strategy for fragile X syndrome therapy
Ekaterina M Shitik1, Anastasia A Velmiskina1, Alexander A Dolskiy1
1State Research Center of Virology and Biotechnology "Vector", Federal Service for Surveillance on Consumer Rights Protection and Human Well-being (FBRI SRC VB "Vector", Rospotrebnadzor), Koltsovo, Novosibirsk Region, Russia.
Abstract:
Fragile X syndrome (FXS) is the most common form of intellectual disability and autism spectrum disorder and is caused by CGG repeat expansion in the promoter region of the FMR1 gene, which encodes fragile X mental retardation protein. This event leads to gene silencing and the loss of gene products through DNA methylation and chromatin remodeling. Due to the pathogenesis of FXS, targeted, symptomatic, and etiological approaches have been developed for its treatment. Despite their rapid development, symptomatic and targeted treatment approaches have numerous limitations; etiological approaches have the greatest potential because they affect the main causes of transcriptional silencing. In this review, we consider three potential etiological therapeutic methods that affect the reactivation of FMR1 gene expression: treatment with inhibitors of chromatin-modifying enzymes, the use of noncoding RNAs and the application of gene therapy. Inhibitors of chromatin-modifying enzymes are not clinically applicable because of their low reactivity and high cytotoxicity, and noncoding RNAs are currently only under study. Thus, we discuss gene therapy as the most promising approach for treating FXS in the near future.
Insights
Fragile X syndrome (FXS) is a leading cause of intellectual disability. Gene therapy shows promise for FXS by targeting FMR1 gene silencing, offering a potential etiological treatment.
Area of Science:
- Genetics and Molecular Biology
- Neuroscience
- Developmental Biology
Background:
- Fragile X syndrome (FXS) is the most common genetic cause of intellectual disability and autism spectrum disorder.
- It results from CGG repeat expansion in the FMR1 gene promoter, leading to gene silencing via DNA methylation and chromatin remodeling.
- Current treatments are largely symptomatic or targeted, with limitations in addressing the root cause.
Purpose of the Study:
- To review and evaluate potential etiological therapeutic approaches for Fragile X syndrome.
- To assess the feasibility and potential of reactivating FMR1 gene expression.
- To identify the most promising future therapeutic strategy for FXS.
Main Methods:
- Review of existing literature on FXS pathogenesis and therapeutic strategies.
- Analysis of three etiological approaches: chromatin-modifying enzyme inhibitors, noncoding RNAs, and gene therapy.
- Evaluation of the efficacy, limitations, and clinical applicability of each approach.
Main Results:
- Chromatin-modifying enzyme inhibitors show low reactivity and high cytotoxicity, limiting clinical use.
- Noncoding RNA therapies are still in the early stages of research and development.
- Gene therapy presents the most promising approach for addressing the primary cause of FXS.
Conclusions:
- Etiological treatments targeting FMR1 gene reactivation hold the greatest potential for FXS.
- Gene therapy is identified as the most viable and promising future therapeutic strategy for Fragile X syndrome.
- Further research and development in gene therapy are crucial for clinical application in FXS treatment.
More Related Videos
08:22A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene
Published on: September 16, 2019
10:59Generation and Characterization of Human Induced Pluripotent Stem Cell-derived Astrocytes Lacking Fragile X Messenger Ribonucleoprotein
Published on: June 6, 2025